Customised, individualised treatment of metastatic non-small-cell lung carcinoma (NSCLC)

Muhammad Furrukh, Mansour Al-Moundhri, Khawaja F. Zahid, Shiyam Kumar, Ikram Burney

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

A series of phase II and randomised phase III trials in Asia and Europe have confirmed recently that advanced stage non-small-cell lung carcinoma patients with adenocarcinoma subtypes harbouring specific mutations when subjected to targeted therapy experience equivalent survival outcomes as those treated with chemotherapy and are spared from its side effects. The concept of chemotherapy for all is fading, and therapy optimisation has emerged as a paradigm shift in treatment. This article briefly describes cellular mechanisms involved in lung carcinogenesis which provide a molecular basis for targeted therapy. Advances in molecular biology have improved our understanding of mechanisms involved in primary or secondary drug resistance. Evolving biomarkers of prognostic and predictive importance, and the impact of translational research on outcomes are also covered. A marker is considered prognostic if it predicts the outcome, regardless of the treatment, and predictive if it predicts the outcome of a specific therapy.

Original languageEnglish
Pages (from-to)202-217
Number of pages16
JournalSultan Qaboos University Medical Journal
Volume13
Issue number2
Publication statusPublished - May 2013

Fingerprint

Non-Small Cell Lung Carcinoma
Molecular Targeted Therapy
Drug Therapy
Translational Medical Research
Therapeutics
Drug Resistance
Molecular Biology
Carcinogenesis
Adenocarcinoma
Biomarkers
Lung
Mutation
Survival

Keywords

  • Bevacizumab
  • Biological markers
  • Carcinoma
  • Epidermal growth factor
  • Erlotinib
  • Lung neoplasm
  • Non-small-cell lung
  • Protein kinase inhibitors
  • Receptor
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Customised, individualised treatment of metastatic non-small-cell lung carcinoma (NSCLC). / Furrukh, Muhammad; Al-Moundhri, Mansour; Zahid, Khawaja F.; Kumar, Shiyam; Burney, Ikram.

In: Sultan Qaboos University Medical Journal, Vol. 13, No. 2, 05.2013, p. 202-217.

Research output: Contribution to journalArticle

@article{007926bf454045cf8e5fc52b5f81bd57,
title = "Customised, individualised treatment of metastatic non-small-cell lung carcinoma (NSCLC)",
abstract = "A series of phase II and randomised phase III trials in Asia and Europe have confirmed recently that advanced stage non-small-cell lung carcinoma patients with adenocarcinoma subtypes harbouring specific mutations when subjected to targeted therapy experience equivalent survival outcomes as those treated with chemotherapy and are spared from its side effects. The concept of chemotherapy for all is fading, and therapy optimisation has emerged as a paradigm shift in treatment. This article briefly describes cellular mechanisms involved in lung carcinogenesis which provide a molecular basis for targeted therapy. Advances in molecular biology have improved our understanding of mechanisms involved in primary or secondary drug resistance. Evolving biomarkers of prognostic and predictive importance, and the impact of translational research on outcomes are also covered. A marker is considered prognostic if it predicts the outcome, regardless of the treatment, and predictive if it predicts the outcome of a specific therapy.",
keywords = "Bevacizumab, Biological markers, Carcinoma, Epidermal growth factor, Erlotinib, Lung neoplasm, Non-small-cell lung, Protein kinase inhibitors, Receptor, Vascular endothelial growth factor",
author = "Muhammad Furrukh and Mansour Al-Moundhri and Zahid, {Khawaja F.} and Shiyam Kumar and Ikram Burney",
year = "2013",
month = "5",
language = "English",
volume = "13",
pages = "202--217",
journal = "Sultan Qaboos University Medical Journal",
issn = "2075-051X",
publisher = "Sultan Qaboos University",
number = "2",

}

TY - JOUR

T1 - Customised, individualised treatment of metastatic non-small-cell lung carcinoma (NSCLC)

AU - Furrukh, Muhammad

AU - Al-Moundhri, Mansour

AU - Zahid, Khawaja F.

AU - Kumar, Shiyam

AU - Burney, Ikram

PY - 2013/5

Y1 - 2013/5

N2 - A series of phase II and randomised phase III trials in Asia and Europe have confirmed recently that advanced stage non-small-cell lung carcinoma patients with adenocarcinoma subtypes harbouring specific mutations when subjected to targeted therapy experience equivalent survival outcomes as those treated with chemotherapy and are spared from its side effects. The concept of chemotherapy for all is fading, and therapy optimisation has emerged as a paradigm shift in treatment. This article briefly describes cellular mechanisms involved in lung carcinogenesis which provide a molecular basis for targeted therapy. Advances in molecular biology have improved our understanding of mechanisms involved in primary or secondary drug resistance. Evolving biomarkers of prognostic and predictive importance, and the impact of translational research on outcomes are also covered. A marker is considered prognostic if it predicts the outcome, regardless of the treatment, and predictive if it predicts the outcome of a specific therapy.

AB - A series of phase II and randomised phase III trials in Asia and Europe have confirmed recently that advanced stage non-small-cell lung carcinoma patients with adenocarcinoma subtypes harbouring specific mutations when subjected to targeted therapy experience equivalent survival outcomes as those treated with chemotherapy and are spared from its side effects. The concept of chemotherapy for all is fading, and therapy optimisation has emerged as a paradigm shift in treatment. This article briefly describes cellular mechanisms involved in lung carcinogenesis which provide a molecular basis for targeted therapy. Advances in molecular biology have improved our understanding of mechanisms involved in primary or secondary drug resistance. Evolving biomarkers of prognostic and predictive importance, and the impact of translational research on outcomes are also covered. A marker is considered prognostic if it predicts the outcome, regardless of the treatment, and predictive if it predicts the outcome of a specific therapy.

KW - Bevacizumab

KW - Biological markers

KW - Carcinoma

KW - Epidermal growth factor

KW - Erlotinib

KW - Lung neoplasm

KW - Non-small-cell lung

KW - Protein kinase inhibitors

KW - Receptor

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=84877797089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877797089&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84877797089

VL - 13

SP - 202

EP - 217

JO - Sultan Qaboos University Medical Journal

JF - Sultan Qaboos University Medical Journal

SN - 2075-051X

IS - 2

ER -